Figure 4.

Effects of bumetanide on epileptic features of Ube3a^m−/p+ mice. (A) Effects of bumetanide on seizure susceptibility induced by flurothyl inhalation. The left and right panels indicate the latencies of myoclonic and tonic seizures, respectively. Bumetanide increases the latency of seizure induction in both wild-type (WT) and Ube3a^m−/p+ mice. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by post-hoc analysis after two-way ANOVA. n = 15–18 for each group. (B) Effects of bumetanide on epileptic discharges in Ube3a^m−/p+ mice. The upper panel shows representative encephalography (EEG) traces taken during the awake state. The left lower panel demonstrates the significantly higher probability for epileptic spike discharges in Ube3a^m−/p+ mice (n = 6) compared to WT animals (n = 6). *p < 0.05 by the unpaired t test. The right lower panel shows the probabilities of epileptic spike discharges before and after bumetanide administration in Ube3a^m−/p+ mice (n = 5). ns not significant by the paired t test. (C) Effects of bumetanide on the relative EEG power spectrum in Ube3a^m−/p+ mice. The upper panel shows the comparison of relative EEG powers in each band during the awake state between WT (n = 11) and Ube3a^m−/p+ (n = 11) groups. *p < 0.05; **p < 0.01 by the unpaired t test. The lower panel shows the relative EEG powers in each frequency band before and after bumetanide administration in Ube3a^m−/p+ mice (n = 5). ns not significant by the paired t test. Bumetanide does not affect the EEG abnormalities of Ube3a^m−/p+ mice.